Savara (NASDAQ:SVRA) Announces Quarterly Earnings Results

Savara (NASDAQ:SVRA) announced its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11), Zacks reports.

Savara Stock Performance

Shares of SVRA traded down $0.38 on Wednesday, reaching $3.45. 1,229,368 shares of the stock traded hands, compared to its average volume of 1,202,390. The stock’s 50-day moving average price is $3.96 and its 200-day moving average price is $4.22. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The firm has a market cap of $567.87 million, a price-to-earnings ratio of -8.24 and a beta of 1.02. Savara has a 12 month low of $3.28 and a 12 month high of $5.70.

Analysts Set New Price Targets

Several analysts have commented on SVRA shares. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Evercore ISI restated an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research note on Wednesday. Finally, HC Wainwright decreased their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Savara currently has an average rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.